Allogene Therapeutics, Inc. Company Profile

08:00 EDT 23rd April 2018 | BioPortfolio

News Articles [722 Associated News Articles listed on BioPortfolio]

Pfizer And Allogene Therapeutics Enter Into Asset Contribution Agreement

NewsPfizer creates an alliance with Allogene Therapeutics to expedite the development of allogeneic CAR T cell therapy.

Pfizer and Allogene Partner for Expedited Development of CAR T Immuno-Oncology Portfolio

NEW YORK & SOUTH SAN FRANCISCO–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contr...

Pfizer To Hold 25% Ownership Stake In Allogene Therapeutics

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Allogene Therapeutics Inc. said that they have entered into an asset contribution agreement for Pfizer's portfolio of assets related to allogeneic c...

Pfizer and Allogene Therapeutics enter into asset contribution agreement for Pfizer's allogeneic CAR T immuno-oncology portfolio

Pfizer Inc. (NYSE:PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contribution agreement for Pfizer's portfolio of assets related to a...

CAR-T startup Allogene raises $300M in Series A funding round

Allogene Therapeutics, a startup headed by former Kite Pharma executives Arie Belldegrun and David Chang, gained $300 million -More- 

Allogene gains 17 assets from Pfizer

Newly launched with $300mm in Series A backing, Allogene Therapeutics Inc. is acquiring from Pfizer Inc. assets that the Big Pharma licensed from Cellectis SA in 2014 and Servier SA in 2015.

Pfizer in deal with Allogene to develop cancer cell therapies

(Reuters) - Pfizer Inc said on Tuesday it would take a 25 percent stake in Allogene Therapeutics to accelerate the development of CAR T cell therapies sourced from donors instead of patients.

Pfizer signs deal with Allogene to develop cancer cell therapy

(Reuters) - Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to further develop its a...

PubMed Articles [411 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Introduction to Volume 1 of JOPT Special Issue.

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [139 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1214 Associated Companies listed on BioPortfolio]

Allogene Therapeutics, Inc.

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Allogene Therapeutics, Inc." on BioPortfolio

We have published hundreds of Allogene Therapeutics, Inc. news stories on BioPortfolio along with dozens of Allogene Therapeutics, Inc. Clinical Trials and PubMed Articles about Allogene Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Allogene Therapeutics, Inc. Companies in our database. You can also find out about relevant Allogene Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record